Leukemia Research Foundation
Meets Standards
Standards For Charity Accountability
Governance
-
Board Oversight
-
Board Size
-
Board Meetings
-
Board Compensation
-
Conflict of Interest
Measuring Effectiveness
-
Effectiveness Policy
-
Effectiveness Report
Finances
-
Program Expenses
-
Fundraising Expenses
-
Accumulating Funds
-
Audit Report
-
Detailed Expense Breakdown
-
Accurate Expense Reporting
-
Budget Plan
Fundraising & Info
-
Truthful Materials
-
Annual Report
-
Website Disclosures
-
Donor Privacy
-
Cause Marketing Disclosures
-
Complaints
Leukemia Research Foundation meets the 20 Standards for Charity Accountability.
Stated Purpose:
The Leukemia Research Foundation’s mission is to cure leukemia by funding innovative research, and to support patients and families.
Year, State Incorporated:
1951, IL
Research grants
As the nation's largest nonprofit focused exclusively on funding leukemia research, our grants are accelerating the development of new and better treatments and an ultimate cure for leukemia.
Patient and family support
Through our patient-centered approach, access to leukemia experts, and nationwide partnerships, our support programs help patients and their loved ones navigate every step of the cancer journey.
For the year ended June 30, 2023, Leukemia Research Foundation's program expenses were:
| Medical research | $2,455,594 |
| Patient outreach and education | $279,178 |
| Patient financial assistance | $179,325 |
| Total Program Expenses | $2,914,097 |
Chief Executive
Kevin Radelet, Executive Director
Chair of the Board
Mr. Blake Brandwein, Board President
Chair's Profession / Business Affiliation
Baxter Healthcare
Board Size
14
Paid Staff Size
6
Method(s) Used:
Direct mail appeals, Invitations to fund raising events, Grant proposals, Internet, Planned giving arrangements
This organization is tax-exempt under section 501(c)(3) of the Internal Revenue Code. It is eligible to receive contributions deductible as charitable donations for federal income tax purposes.
The following information is based on Leukemia Research Foundation's audited financial statements for the year ended June 30, 2023.
Source of Funds
| Contributions | $2,337,109 |
| Corporation and foundation contributions | $903,500 |
| Chapter remittances, net of direct benefits to donors of $71,064 in 2023 | $632,920 |
| Indirect fundraising, net of direct benefit to donors of $27,137 in 2023 | $220,522 |
| Investment income | $81,224 |
| Return of grant funds | $34,847 |
| Release of grant funding obligation | $27,063 |
| Federal and state campaigns | $17,825 |
| Miscellaneous | $144 |
| Total Income | $4,255,154 |
Programs: 81% Fundraising: 10% Administrative: 9%
| Total Income | $4,255,154 |
| Total expenses: | $3,582,486 |
| Program expenses | $2,914,097 |
| Fundraising expenses | $351,425 |
| Administrative expenses | $316,964 |
| Other expenses | $0 |
| Income in Excess of Expenses | $672,668 |
| Beginning Net Assets | $3,452,629 |
| Other Changes In Net Assets | $23,163 |
| Ending Net Assets | $4,148,460 |
| Total Liabilities | $2,716,288 |
| Total Assets | $6,864,748 |
An organization may change its practices at any time without notice. A copy of this report has been shared with the organization prior to publication. It is not intended to recommend or deprecate, and is furnished solely to assist you in exercising your own judgment. If the report is about a charity and states the charity meets or does not meet the Standards for Charity Accountability, it reflects the results of an evaluation of information and materials provided voluntarily by the charity. The name Better Business Bureau is a registered service mark of the International Association of Better Business Bureaus.
This report is not to be used for fundraising or promotional purposes.
RELATED CONTENT
-
Meets Standards
-
Standards Not Met
-
Did Not Disclose
-
Review in Progress
-
Unable to Verify
Report completed by:
BBB of Chicago & Northern Illinois